Welcome to our dedicated page for Ethos Technologies news (Ticker: LIFE), a resource for investors and traders seeking the latest updates and insights on Ethos Technologies stock.
Ethos Technologies Inc. reports developments tied to its digital life insurance platform, which connects consumers, independent agents and insurance carriers through online underwriting and policy issuance tools. The company distributes life insurance products in direct-to-consumer and third-party channels and earns carrier commissions and administrator-service revenue from activated policies.
Recurring updates include quarterly results, direct and third-party channel revenue, policy activation trends, and technology integrations that expand digital purchasing. Company announcements also cover carrier collaborations and product additions, including whole life, final expense, and indexed universal life offerings delivered through Ethos' platform.
Ethos (NYSE:LIFE) and Banner Life expanded their partnership on March 24, 2026 to offer two Ethos-branded whole life products: Simplified Issue Whole Life and Guaranteed Issue Whole Life. The launch extends Ethos’ final expense suite, increases product redundancy to 12 offerings, and targets broader access to affordable permanent protection across select agencies.
Ethos (NASDAQ:LIFE) announced that Peter Colis, co-founder and CEO, will present at The Citizens Technology Conference in San Francisco on March 3, 2026.
The presentation is scheduled for 11:00 AM PT / 2:00 PM ET and will be available as a live audio webcast on investors.ethos.com, with the archive posted for 90 days.
Ethos (NYSE:LIFE) announced a partnership with North American to offer a proprietary Accumulation Indexed Universal Life (IUL) product on Ethos’ digital platform starting Jan 7, 2026. The new IUL will provide eligible consumers up to $2 million of coverage and is marketed for fast issuance, including an instant-decision option with no medical exams for qualifying applicants.
The product features cash-value accumulation, net-zero cost loans, interest and loan bonuses, and nine index option selections. Accumulation IUL will be launched via a limited distribution and aims to simplify application and estate-planning for agents and consumers.
Ethos (NYSE:LIFE) announced a partnership with Aflac (NYSE:AFL) to offer Aflac’s supplemental cancer insurance through Ethos’s digital distribution platform, starting Dec. 18, 2025. The collaboration integrates Aflac’s cancer policy alongside Ethos life products to cover out-of-pocket costs related to cancer diagnosis and treatment, with benefits that begin at annual preventative screenings, pay cash directly to policyholders, have no deductibles, and use streamlined claims processing.
The deal lets Aflac use Ethos’s technology and distribution to deliver a fully digital purchase experience and expand consumer access to supplemental health coverage.
Ethos, a life insurance technology company, has filed a registration statement on Form S-1 with the SEC for its proposed Initial Public Offering (IPO). The company plans to list its Class A common stock on the Nasdaq Global Select Market under the ticker symbol "LIFE".
The IPO will be led by Goldman Sachs & Co. LLC and J.P. Morgan as lead book-running managers, with BofA Securities, Barclays, Citigroup, and Deutsche Bank Securities serving as additional book-running managers. Citizens Capital Markets, William Blair, and Baird will act as co-managers.
The specific details regarding the number of shares and price range for the offering have not yet been determined.
Ethos, a life insurance technology company, has announced a strategic partnership with Lifeforce, the largest longevity medicine platform. The collaboration offers Ethos policyholders a $250 benefit towards Lifeforce's Diagnostic offering, which includes at-home biomarker testing, access to board-certified longevity physicians, personalized treatment protocols, and health coaching.
The partnership complements Ethos' recently launched Indexed Universal Life insurance offering and estate planning tools. Ethos utilizes proprietary technology and real-time data to provide a 100% digital application process with decisions in minutes, eliminating the need for medical exams. The company works with major carriers including Legal & General America, Protective, TruStage, John Hancock, and Ameritas Life Insurance Corp.
[ "New $250 health benefit added for policyholders", "Partnership enhances product offering with longevity care services", "Streamlined 100% digital application process with quick decisions", "Collaboration with major insurance carriers" ]Ethos (NYSE:LIFE), a leading insurtech company, has announced the appointment of William J. Wheeler to its Board of Directors. Wheeler brings over 30 years of financial services leadership experience, having served as Vice Chairman of Athene Holding and President of Americas for MetLife.
Wheeler currently serves as a director at Evercore Inc., chairing its Audit Committee. He joins Ethos' distinguished board alongside co-founders Peter Colis and Lingke Wang, and representatives from Sequoia Capital, Accel, Guidewire Software, Twilio, and former PayPal executives.
Ethos utilizes proprietary technology and real-time data to streamline the life insurance application process, offering customers quick decisions through a digital application without requiring medical exams.
aTyr Pharma announces a change in its Nasdaq stock ticker symbol from 'LIFE' to 'ATYR,' effective June 5, 2024, at market open.
The change reflects the company's focus on advancing its lead therapeutic candidate, efzofitimod, through a pivotal Phase 3 study in pulmonary sarcoidosis and preparing for potential commercialization.
No action is required by existing stockholders, and the company's common stock will continue to be listed on the Nasdaq Capital Market with the same CUSIP.
aTyr is a clinical stage biotech company developing first-in-class medicines based on its proprietary tRNA synthetase platform.
aTyr Pharma announced the granting of nonstatutory stock options to two new employees. These options cover a total of 9,400 shares of common stock, each priced at $1.86 per share, matching the closing price on May 22, 2024. This inducement grant, under Nasdaq Listing Rule 5635(c)(4), is part of the 2022 Inducement Plan. The options will vest over four years, with 25% vesting after one year and the remaining 75% vesting monthly over the next three years. aTyr Pharma focuses on developing novel medications from its tRNA synthetase platform, with its leading candidate being efzofitimod, aimed at treating interstitial lung disease.
aTyr Pharma announced the presentation of data on its lead candidate, efzofitimod, at the ATS 2024 International Conference. This data highlights efzofitimod’s mechanism in modulating myeloid cells, offering anti-inflammatory benefits, particularly for pulmonary sarcoidosis, a form of ILD. The presentation will occur on May 19, 2024, in San Diego, CA.
Efzofitimod interacts with neuropilin-2 (NRP2) receptors, reducing inflammation by modulating macrophages. This discovery marks NRP2 as a new immune target and suggests efzofitimod’s broad therapeutic potential for ILD and other chronic inflammatory diseases.
Efzofitimod is currently in Phase 3 trials for pulmonary sarcoidosis and Phase 2 for systemic sclerosis-related ILD, aiming to provide safer, effective treatments.